Table 2. Non-COVID-19 PICU infections and antibiotic resistance prior to and during the COVID-19 pandemic.
CLABSI, central-line-associated bloodstream infections; VAP, ventilator-associated pneumonia; ESBL, extended-spectrum β-lactamase; PICU, pediatric intensive care unit
| Variable | 2019 | 2020 |
| CLABSI | ||
| Count | 8 (47%) | 5 (50%) |
| Rate | 2.41 | 2.26 |
| Density | 3.37 | 2.21 |
| VAP | ||
| Count | 9 (53%) | 2 (20%) |
| Rate | 2.71 | 0.9 |
| Density | 3.79 | 0.44 |
| Meningitis/ventriculitis | ||
| Count | - | 1 (10%) |
| Rate | - | 0.45 |
| Density | - | 0.44 |
| Decubitus ulcer | ||
| Count | - | 1 (10%) |
| Rate | - | 0.45 |
| Density | - | 0.44 |
| Clinically defined pneumonia | ||
| Count | - | 1 (10%) |
| Rate | - | 0.45 |
| Density | - | 0.44 |
| Resistance: ESBL | ||
| Klebsiella pneumoniae (%) | 83.33 | 50 |
| Resistance: KARBAPENEM | ||
| Acinetobacter baumannii (%) | 100 | 100 |
| Klebsiella pneumoniae (%) | 66.67 | 50 |
| Pseudomonas aeruginosa (%) | 60 | - |
| Resistance: KOLISTIN | ||
| Acinetobacter baumannii (%) | 0 | 16.67 |
| Resistance: VRE | ||
| Enterococcus faecalis (%) | 100 | - |
| Enterococcus faecium (%) | 100 | - |